Xevudy Helps GSK Ride Out Depressed Shingrix Sales
But COVID-19 Profits Will Drop In 2022
GlaxoSmithKline is preparing for the long-awaited spin-out of its consumer division later this year but needs to see Shingrix bounce back from its pandemic blues to help the company reignite growth.
